Treatment of neuromyelitis optica: Review and recommendations
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to tr...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2012
|
| _version_ | 1826291719732199424 |
|---|---|
| author | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Isabel Leite, M Levy, M Marignier, R Nakashima, I Palace, J De Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository |
| author_facet | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Isabel Leite, M Levy, M Marignier, R Nakashima, I Palace, J De Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository |
| author_sort | Kimbrough, D |
| collection | OXFORD |
| description | Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices. Copyright 2012 Elsevier B.V. |
| first_indexed | 2024-03-07T03:03:39Z |
| format | Journal article |
| id | oxford-uuid:b1c7ac92-3c0a-4a8b-a833-06daa7ab2ac4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:03:39Z |
| publishDate | 2012 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:b1c7ac92-3c0a-4a8b-a833-06daa7ab2ac42022-03-27T04:06:45ZTreatment of neuromyelitis optica: Review and recommendationsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b1c7ac92-3c0a-4a8b-a833-06daa7ab2ac4EnglishSymplectic Elements at OxfordElsevier2012Kimbrough, DFujihara, KJacob, ALana-Peixoto, MIsabel Leite, MLevy, MMarignier, RNakashima, IPalace, JDe Seze, JStuve, OTenembaum, SNTraboulsee, AWaubant, EWeinshenker, BGWingerchuk, DGuthy Jackson Charitable Foundation Clinical Consortium and BiorepositoryNeuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to traditional MS immunomodulators such as interferons. Preventive therapy in NMO has focused on a range of immunosuppressive medications, none of which have been validated in a rigorous randomized trial. However, multiple retrospective and a few recent prospective studies have provided evidence for the use of six medications for the prevention of NMO exacerbations: azathioprine, rituximab, mycophenolate mofetil, prednisone, methotrexate and mitoxantrone. This review provides a comprehensive analysis of each of these medications in NMO and concludes with a set of recommended consensus practices. Copyright 2012 Elsevier B.V. |
| spellingShingle | Kimbrough, D Fujihara, K Jacob, A Lana-Peixoto, M Isabel Leite, M Levy, M Marignier, R Nakashima, I Palace, J De Seze, J Stuve, O Tenembaum, SN Traboulsee, A Waubant, E Weinshenker, BG Wingerchuk, D Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository Treatment of neuromyelitis optica: Review and recommendations |
| title | Treatment of neuromyelitis optica: Review and recommendations |
| title_full | Treatment of neuromyelitis optica: Review and recommendations |
| title_fullStr | Treatment of neuromyelitis optica: Review and recommendations |
| title_full_unstemmed | Treatment of neuromyelitis optica: Review and recommendations |
| title_short | Treatment of neuromyelitis optica: Review and recommendations |
| title_sort | treatment of neuromyelitis optica review and recommendations |
| work_keys_str_mv | AT kimbroughd treatmentofneuromyelitisopticareviewandrecommendations AT fujiharak treatmentofneuromyelitisopticareviewandrecommendations AT jacoba treatmentofneuromyelitisopticareviewandrecommendations AT lanapeixotom treatmentofneuromyelitisopticareviewandrecommendations AT isabelleitem treatmentofneuromyelitisopticareviewandrecommendations AT levym treatmentofneuromyelitisopticareviewandrecommendations AT marignierr treatmentofneuromyelitisopticareviewandrecommendations AT nakashimai treatmentofneuromyelitisopticareviewandrecommendations AT palacej treatmentofneuromyelitisopticareviewandrecommendations AT desezej treatmentofneuromyelitisopticareviewandrecommendations AT stuveo treatmentofneuromyelitisopticareviewandrecommendations AT tenembaumsn treatmentofneuromyelitisopticareviewandrecommendations AT traboulseea treatmentofneuromyelitisopticareviewandrecommendations AT waubante treatmentofneuromyelitisopticareviewandrecommendations AT weinshenkerbg treatmentofneuromyelitisopticareviewandrecommendations AT wingerchukd treatmentofneuromyelitisopticareviewandrecommendations AT guthyjacksoncharitablefoundationclinicalconsortiumandbiorepository treatmentofneuromyelitisopticareviewandrecommendations |